Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel

Journal of Controlled Release

Volumn 91, Issue 3, 2003, Pages 417-429

  Immordino, Maria Laura ^a   Brusa, Paola ^a   Arpicco, Silvia ^a   Stella, Barbara ^a   Dosio, Franco ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biodistribution; Liposomes; PEGylated liposomes; Pharmacokinetics; Taxanes

Indexed keywords

ETHANOL; TOXICITY; TUMORS;

LIPOSOMES;

CHROMOSOMES;

ANTINEOPLASTIC AGENT; CARBON 13; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLETHANOLAMINE METHOXYPOLYETHYLENE GLYCOL CONJUGATE; DOCETAXEL; EGG YOLK PHOSPHATIDYLCHOLINE; LIPOSOME; MACROGOL; PACLITAXEL; PHOSPHATIDYLCHOLINE; TAXANE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG STABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0042073230     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00271-2     Document Type: Article

References (43)

1. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48:1997;353-374.
2. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 344:1994;1267-1272.
3. Fulton B., Spencer C.M. Docetaxel, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 51:(6):1996;1075-1092.
4. Earhart R.H. Docetaxel (Taxotere): preclinical and general clinical information. Semin. Oncol. 26:(5):1999;8-13.
5. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl. J. Med. 332:1995;1004-1014.
6. Horwitz S.B. Mechanism of action of Taxol. Trends Pharmacol. Sci. 13:1992;134-136.
7. Lavelle F., Bissery M.C., Combeau C., Riou J.F., Vrignaud P., André S. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol. 22:(2):1995;3-16.
8. Bissery M.C. Preclinical pharmacology of docetaxel. Eur. J. Cancer. 31A:(4):1995;S1-S6.
9. Vanhoefer U., Cao S., Harstrick A., Seeber S., Rustum Y.M. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann. Oncol. 8:1997;1221-1228.
10. Capri G., Tarenzi E., Fulfaro F., Gianni L. The role of taxanes in the treatment of breast cancer. Semin. Oncol. 23:(1, Suppl. 2):1996;68-75.
11. Kaye S.B. Taxoids. Eur. J. Cancer. 31A:(5):1995;824-826.
12. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.L., Trump D., Baker J.R., VanEcho D.A., VonHoff D.D., Leyland-Jones B. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8:1990;1263-1268.
13. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:1994;S11-S14.
14. Verweij J. Docetaxel (Taxotere™): a new anti-cancer drug with promising potential? Br. J. Cancer. 70:1994;183-184.
15. Piccart M.J., Di Leo A. Future Perspectives of docetaxel (Taxotere) in front-line therapy. Semin. Oncol. 24:(4, Suppl. 10):1997;S10-27-S10-33.
16. Airoldi M., Cattel L., Pedani F., Marchionatti S., Tagini V., Bumma C., Recalenda V. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res. Treat. 70:2001;185-195.
17. Cattel L., Recalenda V., Airoldi M., Tagini V., Arpicco S., Brusa P., Bumma C. A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco. 56:2001;779-784.
18. Lasic D.D. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J. Control. Release. 48:1997;203-222.
19. Woodle M.C. Sterically stabilized liposome therapeutics. Adv. Drug. Deliv. Rev. 16:1995;249-265.
20. Sharma A., Straubinger R.M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11:(6):1994;889-896.
21. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res. 53:1993;5877-5881.
22. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71:1997;103-107.
23. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Control. Release. 47:1997;293-304.
24. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release. 63:2000;19-30.
25. Ceruti M., Crosasso P., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J. Control. Release. 63:2000;141-153.
26. Rouser G., Fleischer J., Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:1970;494-496.
27. Sharma A., Conway W.D., Straubinger R.M. Reversed-phase high-performance liquid chromatographic determination of taxol in mouse plasma. J. Chromatogr. B. 655:1994;315-319.
28. Brusa P., Dosio F., Pacchioni D., Delprino L., Grosa G., Bussolati G., Cattel L. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice. J. Pharm. Sci. 83:1993;514-519.
29. Brusa P., Dosio F., Ceruti M., Grosa G., Cattel L. 2-aza-2,3-dihydrosqualene: biodistribution and pharmacokinetic properties in mice. Atti Accad. Sci. Torino. 127:(5-6):1993;239-256.
30. Wenk M.R., Fahr A., Resza R., Seelig J. Paclitaxel partitioning into lipid bilayers. J. Pharm. Sci. 85:1996;228-231.
31. Moyna G., Williams H.J., Scott A.I. Conformational studies of paclitaxel analogues modified at the C-2′ position in hydrophobic and hydrophilic solvent system. J. Med. Chem. 40:1997;3305-3311.
32. Mastropaolo D., Camerman A., Luo Y., Brayer G.D., Camerman N. Crystal and molecular structure of paclitaxel (taxol). Proc. Natl. Acad. Sci. USA. 92:1995;6920-6924.
33. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposome formulations. Pharm. Res. 13:1996;718-724.
34. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Effect of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implication in liposomal drug delivery. Pharm. Res. 13:1996;710-717.
35. Bedu-Addo F.K., Huang L. Interaction of PEG-phospholipid conjugates with phospholipid: implication in liposomal drug delivery. Adv. Drug Deliv. Rev. 16:1995;235-247.
36. Chervinsky D.S., Brecher M.L., Hoelcle M.J. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. J. Anticancer Res. 13:1993;93-96.
37. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids. 64:1993;249-262.
38. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C.G., Rabello E., Cass Y., Peretz T., Sulkes A., Chisin R., Berenholz Y. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33:1994;779-786.
39. Unezaki S., Maruyama K., Ishida O., Suginaka A., Hosoda J., Iwatsuru M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipatic poly(ethylene glycol). Int. J. Pharm. 126:1995;41-48.
40. Daemen T., Regts J., Meesters M., Ten Kate M.T., Bakker-Woudenberg I.A.J.M., Scherphof G.L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release. 44:1997;1-9.
41. Allen T.M., Hansen C.B. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta. 1068:1991;133-141.
42. Allen T.M., Hansen C.B., Lopez de Menezes D.E. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev. 16:1995;267-284.
43. Harashima H., Yamane C., Cume Y., Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J. Pharm. Biopharm. 21:1993;299-308.